Free Trial

Ensysce Biosciences (ENSC) Competitors

Ensysce Biosciences logo
$2.05 -0.01 (-0.49%)
Closing price 08/15/2025 04:00 PM Eastern
Extended Trading
$2.10 +0.05 (+2.24%)
As of 08/15/2025 07:50 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

ENSC vs. CMMB, BCAB, PASG, ASBP, SYBX, HOTH, LPCN, LEXX, BLRX, and CASI

Should you be buying Ensysce Biosciences stock or one of its competitors? The main competitors of Ensysce Biosciences include Chemomab Therapeutics (CMMB), BioAtla (BCAB), Passage Bio (PASG), Aspire Biopharma (ASBP), Synlogic (SYBX), Hoth Therapeutics (HOTH), Lipocine (LPCN), Lexaria Bioscience (LEXX), BioLineRx (BLRX), and CASI Pharmaceuticals (CASI). These companies are all part of the "pharmaceutical products" industry.

Ensysce Biosciences vs. Its Competitors

Ensysce Biosciences (NASDAQ:ENSC) and Chemomab Therapeutics (NASDAQ:CMMB) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, institutional ownership, earnings, valuation, media sentiment, profitability, analyst recommendations and risk.

5.6% of Ensysce Biosciences shares are held by institutional investors. Comparatively, 46.1% of Chemomab Therapeutics shares are held by institutional investors. 7.9% of Ensysce Biosciences shares are held by insiders. Comparatively, 11.9% of Chemomab Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Chemomab Therapeutics has a consensus target price of $8.50, indicating a potential upside of 813.98%. Given Chemomab Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Chemomab Therapeutics is more favorable than Ensysce Biosciences.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Ensysce Biosciences
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Chemomab Therapeutics
0 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
3.00

Ensysce Biosciences has a beta of 1, indicating that its stock price has a similar volatility profile to the S&P 500.Comparatively, Chemomab Therapeutics has a beta of 0.52, indicating that its stock price is 48% less volatile than the S&P 500.

In the previous week, Chemomab Therapeutics had 1 more articles in the media than Ensysce Biosciences. MarketBeat recorded 6 mentions for Chemomab Therapeutics and 5 mentions for Ensysce Biosciences. Ensysce Biosciences' average media sentiment score of 0.70 beat Chemomab Therapeutics' score of 0.65 indicating that Ensysce Biosciences is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Ensysce Biosciences
0 Very Positive mention(s)
1 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Chemomab Therapeutics
0 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
1 Very Negative mention(s)
Positive

Ensysce Biosciences has higher revenue and earnings than Chemomab Therapeutics. Chemomab Therapeutics is trading at a lower price-to-earnings ratio than Ensysce Biosciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Ensysce Biosciences$5.21M1.17-$7.99M-$6.54-0.31
Chemomab TherapeuticsN/AN/A-$13.94M-$0.76-1.22

Chemomab Therapeutics has a net margin of 0.00% compared to Ensysce Biosciences' net margin of -88.76%. Chemomab Therapeutics' return on equity of -88.15% beat Ensysce Biosciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Ensysce Biosciences-88.76% -167.23% -104.59%
Chemomab Therapeutics N/A -88.15%-70.00%

Summary

Chemomab Therapeutics beats Ensysce Biosciences on 10 of the 15 factors compared between the two stocks.

Get Ensysce Biosciences News Delivered to You Automatically

Sign up to receive the latest news and ratings for ENSC and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ENSC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

ENSC vs. The Competition

MetricEnsysce BiosciencesMED IndustryMedical SectorNASDAQ Exchange
Market Cap$6.11M$3.09B$5.66B$9.82B
Dividend YieldN/A2.23%3.79%4.07%
P/E Ratio-0.5120.3830.5825.12
Price / Sales1.17356.76462.42114.82
Price / CashN/A42.3037.4059.05
Price / Book1.998.659.096.18
Net Income-$7.99M-$54.65M$3.25B$264.89M
7 Day Performance-5.96%6.58%7.32%4.18%
1 Month Performance-5.09%7.54%5.41%1.99%
1 Year Performance-66.51%13.73%30.66%24.22%

Ensysce Biosciences Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
ENSC
Ensysce Biosciences
0.6358 of 5 stars
$2.05
-0.5%
N/A-65.2%$6.11M$5.21M-0.5110News Coverage
Earnings Report
Analyst Revision
CMMB
Chemomab Therapeutics
3.4671 of 5 stars
$1.00
-2.4%
$8.50
+750.0%
-13.9%$19.33MN/A-1.3220News Coverage
Earnings Report
Upcoming Earnings
Short Interest ↓
BCAB
BioAtla
2.3292 of 5 stars
$0.33
+0.5%
$5.00
+1,408.3%
-80.4%$19.28M$11M-0.2760News Coverage
Analyst Downgrade
Analyst Revision
PASG
Passage Bio
3.7952 of 5 stars
$5.74
flat
$150.00
+2,513.2%
-55.4%$17.91MN/A-0.28130News Coverage
Earnings Report
Analyst Forecast
Analyst Revision
Gap Down
ASBP
Aspire Biopharma
N/A$0.36
+1.2%
N/AN/A$17.85MN/A0.00N/ANews Coverage
Earnings Report
SYBX
Synlogic
0.9737 of 5 stars
$1.50
+1.4%
N/A+4.2%$17.31M$10K-0.6080Short Interest ↑
Gap Up
HOTH
Hoth Therapeutics
3.1195 of 5 stars
$1.40
+7.3%
$4.00
+185.7%
+107.4%$17.24MN/A-1.234Earnings Report
Short Interest ↓
Gap Down
LPCN
Lipocine
2.8967 of 5 stars
$3.13
-0.6%
$9.00
+187.5%
-17.2%$16.85M$11.20M-3.0710News Coverage
LEXX
Lexaria Bioscience
3.7982 of 5 stars
$0.88
+2.9%
$4.00
+357.1%
-74.0%$16.63M$460K-1.317News Coverage
Short Interest ↓
BLRX
BioLineRx
3.3221 of 5 stars
$3.84
-0.8%
$26.00
+577.1%
-86.3%$16.50M$22.34M-0.4440News Coverage
Earnings Report
Gap Down
CASI
CASI Pharmaceuticals
4.0892 of 5 stars
$1.95
+51.2%
$4.00
+105.1%
-63.7%$15.87M$31.37M-0.76180High Trading Volume

Related Companies and Tools


This page (NASDAQ:ENSC) was last updated on 8/16/2025 by MarketBeat.com Staff
From Our Partners